New hope for pancreatic cancer: targeted drug combo enters human trials

NCT ID NCT07444541

Recruiting now Disease control Sponsor: Anova Innovation Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests a new biologic drug called ANO31905 combined with standard chemotherapy as a first treatment for people with advanced pancreatic cancer that has a specific marker (CLDN18.2). The trial has two phases: first to find a safe dose, then to see if the combination shrinks tumors. About 84 participants will be enrolled, and treatment may last up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ANO31905 (a biologic drug) combined with chemotherapy (gemcitabine and nanoparticle albumin-bound paclitaxel)
What this could lead to: If it works, this could offer a new first-line treatment option for people with a specific type of advanced pancreatic cancer, potentially shrinking tumors and extending life.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 84 participants, so results are preliminary. The drug may cause serious side effects like cytokine release syndrome, and it may not work better than standard chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

California Research Institute
RECRUITING

Los Angeles, California, 90027, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.